US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain
UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts -- marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue in excess of the acquisition costs of the drugs,
A new Federal Trade Commission (FTC) report found that the three largest Pharmacy Benefit Managers (PBMs) have taken in large ...
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...
Hosted on MSN2d
What You Need To Know Ahead of CVS Health's Earnings ReleaseWith a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback